EVAL Foundation For practitioners Updated September 12, 2024

ATRIA Bleeding Risk Score

Determines bleeding risk for patients being considered for warfarin anticoagulation

Add to Library

Males: Hemoglobin <13 g/dL 

Females: Hemoglobin <12 g/dL

 

Glomerular filtration rate <30mL/min or dialysis-dependent

Example: GI bleed or intracranial hemorrhage

0%

Reference

Summary

The ATRIA Bleeding Risk Score considers major and minor risk of hemorrhage and bleeding in patients prior to beginning warfarin therapy.

  • The ATRIA study included patients with non-valvular, non-transient atrial fibrillation.
  • Major hemorrhage was defined as fatal, requiring transfusion of ≥2 units pRBCs, or hemorrhage into critical anatomic site (intracranial, retroperitoneal, etc.)

 

Criteria

 

Risk FactorPoint Value
Anemia3
Severe Renal Disease/Dialysis3
Age ≥75 2
Prior Hemorrhage1
Hypertension 1

 

Results

 

Risk LevelPointsAnnual Risk of HemorrhageRecommendation
Low Risk<40.76%Reasonable to start warfarin therap
Intermediate Risk42.6%Alternatives to warfarin therapy can be considered
High Risk>45.8%Alternatives to warfarin therapy ought to be strongly considered

 

 

  • Jennifer Glen , DNP, FNP-BC — EVAL Health, Chief Medical Officer